Home > Boards > US Listed > Medical - Healthcare > Orasure Technologies (OSUR)

More nice news this AM. This biotech is

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
HokieHead Member Profile
Member Level 
Followed By 819
Posts 52,828
Boards Moderated 6
Alias Born 09/30/04
160x600 placeholder
OraSure’s Oragene®•Dx Saliva Collection Kit Included in Industry’s First FDA Authorization for a Whole Exome Sequencin... GlobeNewswire Inc. - 1/21/2021 6:00:00 AM
OraSure Technologies Announces 2021 Annual Meeting Date GlobeNewswire Inc. - 1/8/2021 6:00:00 AM
OraSure Technologies to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/5/2021 6:00:00 AM
OraSure’s OMNIgene®·ORAL Device Included in EUA Amendment Granted to 3B BlackBio Biotech India for SARS-CoV-2 Test GlobeNewswire Inc. - 12/23/2020 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/21/2020 4:46:28 PM
OraSure Technologies Provides Update on Its Emergency Use Authorization Application for Its Lab-based Oral Fluid SARS-CoV-2 ... GlobeNewswire Inc. - 12/21/2020 4:01:00 PM
OraSure Technologies to Present at the 2020 Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
OraSure Technologies to Commemorate World AIDS Day by Ringing NASDAQ Closing Bell GlobeNewswire Inc. - 11/30/2020 7:00:00 AM
OraSure Technologies to Present at the Stephens Annual Investment Conference 2020 GlobeNewswire Inc. - 11/12/2020 7:00:00 AM
Clinical Reference Laboratory to Market Most Cost-Effective, Gold-Standard Self-Collected COVID-19 Saliva Test Directly to Co... PR Newswire (US) - 11/9/2020 8:02:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 4:58:40 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 4:21:49 PM
OraSure Technologies, Inc. Announces Third Quarter 2020 Financial Results and Provides Update on COVID-19 Developments GlobeNewswire Inc. - 11/4/2020 4:01:00 PM
OraSure’s DNA Genotek Subsidiary Receives FDA Emergency Use Authorization for its ORAcollect®·RNA Saliva Collection Devic... GlobeNewswire Inc. - 11/3/2020 7:00:00 AM
OraSure Technologies to Hold 2020 Third Quarter Earnings Conference Call  Wednesday, November 4, 2020, 5:00 p.m. ET GlobeNewswire Inc. - 10/21/2020 6:00:10 AM
OraSure’s OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2 GlobeNewswire Inc. - 10/19/2020 6:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/28/2020 4:59:05 PM
OraSure’s ORAcollect®·RNA Device Included in EUA Granted to Quadrant Biosciences Inc. for COVID-19 Test GlobeNewswire Inc. - 9/24/2020 6:00:10 AM
Former CEO of H2O+ Beauty, Former Chief Chemist of MAC Cosmetics Launch Innovative Skincare Brand Using First-Ever Scientific... GlobeNewswire Inc. - 9/15/2020 12:00:10 PM
Correction to Rapid Covid-19 Tests Article (Sept. 8) Dow Jones News - 9/9/2020 1:02:00 PM
OraSure’s ORAcollect®·RNA Device Included in EUA Granted to MiraDx Inc. for SARS-CoV-2 Test GlobeNewswire Inc. - 9/3/2020 4:30:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/1/2020 6:00:36 AM
OraSure Technologies to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 8/27/2020 4:30:10 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/26/2020 4:31:44 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/10/2020 4:59:30 PM
HokieHead Member Level  Tuesday, 05/12/20 08:26:50 AM
Re: None
Post # of 368 
More nice news this AM. This biotech is turning in to a beast. In since $11 area and dollar costing the whole way up for long term portfolio.

OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
May 12 2020 - 08:00AM GlobeNewswire Inc.

OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service.
The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known. The unification elevates Diversigen as the cornerstone brand for microbiome services in the industry.

The combined organization includes scientific experts representing more than a century of microbiome experience and over 300 articles in respected scientific publications with more than 100,000 citations.

“The new Diversigen brand reflects the combined strength and innovation of these two microbiome service pioneers and positions the OraSure family of companies as an industry leader in this fast-growing industry. Together they will enable us to expand our services as we work to advance global health and bring our customers the tools, services and data-driven insights they need to get reliable, actionable answers to their most critical scientific and healthcare questions,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer, OraSure Technologies, Inc.

All services previously offered under the CoreBiome brand will continue to be available from Diversigen, offering the microbiome market unparalleled choice in sequencing, bioinformatics and analysis services.

The rebrand was implemented after in-depth research, market analysis, and customer conversations. A new Diversigen logo will bring a sharp new visual identity, representing the best of both CoreBiome and Diversigen and characterizes the brand as smart, market-driven, and innovative.

The new Diversigen website is available at diversigen.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences